Last reviewed · How we verify
CD123 CAR-T cells — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
CD123 CAR-T cells (CD123 CAR-T cells) — Chongqing Precision Biotech Co., Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| CD123 CAR-T cells TARGET | CD123 CAR-T cells | Chongqing Precision Biotech Co., Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- CD123 CAR-T cells CI watch — RSS
- CD123 CAR-T cells CI watch — Atom
- CD123 CAR-T cells CI watch — JSON
- CD123 CAR-T cells alone — RSS
Cite this brief
Drug Landscape (2026). CD123 CAR-T cells — Competitive Intelligence Brief. https://druglandscape.com/ci/cd123-car-t-cells. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing